Viking Therapeutics, Inc. (NASDAQ:VKTX) is losing money like it’s going out of style. The biotech’s total revenue this year matches its total revenue last year — zip, zero, nada. At best, Viking is still several years away from even possibly winning approval for its first drug.
So if you ask me whether or not Viking Therapeutics stock is a buy, my answer is an enthusiastic… “yes.”
That’s my answer, at least, for aggressive investors. Despite all of the negatives that I ticked off for Viking, I really like this stock as a speculative play.
Image source: Getty Images.
Similar drugs, very different valuations
The biggest reason why I think so highly of Viking Therapeutics’ prospects is that I also think highly of Madrigal Pharmaceuticals’ (NASDAQ:MDGL) prospects. In May, Madrigal announced really good results from a phase 2 clinical study of its lead candidate MGL-3196 in treating non-alcoholic steatohepatitis (NASH).
Hot Biotech Stocks For 2019: FMC Technologies, Inc.(FTI)
- [By Dan Caplinger]
Energy stocks had a tough 2018, as an initial bounce in crude oil prices gave way to weakness toward the end of the year. Yet 2019 started on a positive footing for the sector, and offshore and land-based drilling services specialist TechnipFMC (NYSE:FTI) saw its stock regain a significant portion of its losses from 2018 during the first couple of months of the year.
- [By Chris Lange]
The S&P 500 stock posting the largest daily percentage loss ahead of the close was TechnipFMC PLC (NYSE: FTI) which traded down about 8% at $22.66. The stock’s 52-week range is $18.20 to $34.39. Volume was about 7.7 million compared to the daily average volume of 4.4 million.
- [By Stephan Byrd]
Get a free copy of the Zacks research report on TechnipFMC (FTI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Hot Biotech Stocks For 2019: Bellerophon Therapeutics, Inc.(BLPH)
- [By Stephan Byrd]
Press coverage about Bellerophon Therapeutics (NASDAQ:BLPH) has trended somewhat positive on Thursday, according to Accern. Accern rates the sentiment of news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Bellerophon Therapeutics earned a news impact score of 0.14 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 46.948363531679 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
- [By Shane Hupp]
Bellerophon Therapeutics Inc (NASDAQ:BLPH) shares traded up 10% during mid-day trading on Monday after an insider bought additional shares in the company. The stock traded as high as $0.91 and last traded at $0.88. 18,690 shares were traded during mid-day trading, a decline of 95% from the average session volume of 388,757 shares. The stock had previously closed at $0.80.
- [By Money Morning Staff Reports]
However, it’s unlikely Netlist repeats these returns anytime soon. After looking at last week’s top performing penny stocks, we’ll show you a penny stock on the verge of jumping over 230%…
Penny Stock Current Share Price Last Week’s Gain
Netlist Inc. (Nasdaq: NLST) $0.83 542.67%
Mannkind Corp. (Nasdaq: MNKD) $1.80 79.09%
Fred’s Inc. (Nasdaq: FRED) $2.49 73.68%
Delcath Systems Inc. (OTCMKTS: DCTH) $3.70 72.63%
Gemphire Therapeutics Inc. (Nasdaq: GEMP) $1.96 50.71%
Bellerophon Therapeutics Inc. (Nasdaq: BLPH) $1.05 47.98%
Cel-Sci Corp. (NYSE: CVM) $3.78 44.78%
ParkerVision Inc. (OTCMKTS: PRKR) $0.60 29.42%
Superior Drilling Products Inc. (NYSE: SDPI) $2.63 29.23%
LiqTech International Inc. (NYSE: LIQT) $1.50 25.20%
How to Profit off This $11.1 Billion Money Pool: By following a few simple steps, one IRS directive could help set you up to receive checks of up to $1,795 every single month thanks to a genius investment. Learn more…
Hot Biotech Stocks For 2019: The York Water Company(YORW)
- [By Ethan Ryder]
BidaskClub downgraded shares of York Water (NASDAQ:YORW) from a hold rating to a sell rating in a research report report published on Thursday.
Separately, Hilliard Lyons raised shares of York Water from an underperform rating to a neutral rating in a research report on Thursday, March 8th.
- [By Logan Wallace]
York Water (NASDAQ:YORW) was upgraded by equities research analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a research note issued to investors on Saturday.